The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment

Edward J. Gane, Sophie Metivier, Ronald Nahass, Michael Ryan, Catherine A. Stedman, Evguenia S. Svarovskaia, Hongmei Mo, Brian Doehle, Hadas Dvory‐Sobol, Charlotte Hedskog, Ming Lin, Diana M. Brainard, Jenny C. Yang, John G. McHutchison, Mark Sulkowski, Ziad Younes, Eric Lawitz – 22 June 2017 – S282T in NS5B is the primary amino acid substitution associated with resistance to sofosbuvir (SOF) but has rarely been detected in patients treated with a SOF‐based regimen.

Long‐term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma

Myron J. Tong, Alexander A. Rosinski, Claiborne T. Huynh, Steven S. Raman, David S.K. Lu – 21 June 2017 – Hepatocellular carcinoma (HCC) is the main cause of mortality in patients with chronic viral hepatitis (CVH). We determined the impact of surveillance and treatments on long‐term outcomes in patients with CVH who developed HCC. Between 1984 and 2014, 333 patients with HCC and with hepatitis B or hepatitis C virus infection were evaluated.

The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis

Guillaume Wettstein, Jean‐Michel Luccarini, Laurence Poekes, Patrick Faye, Francine Kupkowski, Vanessa Adarbes, Evelyne Defrêne, Céline Estivalet, Xavier Gawronski, Ingrid Jantzen, Alain Philippot, Julien Tessier, Pascale Tuyaa‐Boustugue, Fiona Oakley, Derek A. Mann, Isabelle Leclercq, Sven Francque, Irena Konstantinova, Pierre Broqua, Jean‐Louis Junien – 19 June 2017 – IVA337 is a pan‐peroxisome proliferator‐activated receptor (PPAR) agonist with moderate and well‐balanced activity on the three PPAR isoforms (α, γ, δ).

Subscribe to